IPM

The International Partnership for Microbicides (IPM) was established to accelerate the discovery, development and accessibility of microbicides to prevent transmission of HIV for women in developing countries. Tibotec's first NNRTI in clinical development, TMC120, was licensed to IPM for its development as a vaginal microbicide in 2004.



MEDIVIR

Medivir AB and Tibotec Pharmaceuticals Ltd, entered into a license and research collaboration agreement on Hepatitis C in 2004. The goal of the research collaboration is to discover and develop orally active protease inhibitors of Hepatitis C.